Merck & Co., Inc. (NYSE:MRK – Get Free Report) issued its quarterly earnings results on Thursday. The company reported $2.07 EPS for the quarter, topping the consensus estimate of $1.94 by $0.13, Briefing.com reports. Merck & Co., Inc. had a net margin of 0.61% and a return on equity of 9.33%. The firm had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.21 billion. During the same quarter in the prior year, the business posted $1.40 earnings per share. Merck & Co., Inc.’s revenue for the quarter was up 8.9% compared to the same quarter last year. Merck & Co., Inc. updated its FY 2024 guidance to 8.530-8.650 EPS and its FY24 guidance to $8.53-8.65 EPS.
Merck & Co., Inc. Stock Performance
Shares of NYSE:MRK traded up $0.53 on Friday, reaching $131.25. 5,122,029 shares of the company’s stock were exchanged, compared to its average volume of 8,300,212. The firm has a market capitalization of $332.46 billion, a price-to-earnings ratio of 937.57, a PEG ratio of 1.65 and a beta of 0.38. Merck & Co., Inc. has a fifty-two week low of $99.14 and a fifty-two week high of $133.10. The business’s 50-day moving average is $126.34 and its two-hundred day moving average is $115.69. The company has a quick ratio of 1.00, a current ratio of 1.25 and a debt-to-equity ratio of 0.89.
Insiders Place Their Bets
In other Merck & Co., Inc. news, EVP Steven Mizell sold 50,694 shares of the stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the sale, the executive vice president now directly owns 23,619 shares of the company’s stock, valued at $2,991,346.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Joseph Romanelli sold 1,000 shares of the stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total value of $124,890.00. Following the sale, the insider now owns 19,569 shares of the company’s stock, valued at approximately $2,443,972.41. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Steven Mizell sold 50,694 shares of the stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the completion of the sale, the executive vice president now directly owns 23,619 shares in the company, valued at approximately $2,991,346.35. The disclosure for this sale can be found here. 0.09% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
About Merck & Co., Inc.
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
See Also
- Five stocks we like better than Merck & Co., Inc.
- Insider Selling Explained: Can it Inform Your Investing Choices?
- 3 Stocks Leading the U.S. Agriculture Comeback
- 3 Tickers Leading a Meme Stock Revival
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Stock Sentiment Analysis: How it Works
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.